Rani Therapeutics Holdings, Inc.

NasdaqGM RANI

Rani Therapeutics Holdings, Inc. Price to Earnings Ratio (P/E) on February 05, 2025: -2.99

Rani Therapeutics Holdings, Inc. Price to Earnings Ratio (P/E) is -2.99 on February 05, 2025, a 47.87% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Rani Therapeutics Holdings, Inc. 52-week high Price to Earnings Ratio (P/E) is -2.60 on January 10, 2025, which is 13.19% above the current Price to Earnings Ratio (P/E).
Rani Therapeutics Holdings, Inc. 52-week low Price to Earnings Ratio (P/E) is -12.54 on April 17, 2024, which is -319.09% below the current Price to Earnings Ratio (P/E).
Rani Therapeutics Holdings, Inc. average Price to Earnings Ratio (P/E) for the last 52 weeks is -5.47.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: RANI

Rani Therapeutics Holdings, Inc.

CEO	Mr. Talat Imran
IPO Date	July 30, 2021
Location	United States
Headquarters	2051 Ringwood Avenue
Employees	140
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Vaccines

Description

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.

Key trends

Past 5 years